Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 76,928 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 76,928 shares of the stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $0.37, for a total value of $28,463.36. Following the sale, the director owned 300,283 shares in the company, valued at $111,104.71. The trade was a 20.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total value of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total value of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.46, for a total value of $12,741.08.
• On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.48, for a total value of $38,808.96.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $31,936.50.

Werewolf Therapeutics Stock Down 2.5%

HOWL stock opened at $0.37 on Thursday. The business’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $0.72. Werewolf Therapeutics, Inc. has a twelve month low of $0.36 and a twelve month high of $2.38. The firm has a market cap of $17.74 million, a price-to-earnings ratio of -0.29 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Research analysts expect that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP grew its stake in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the period. Regal Investment Advisors LLC lifted its stake in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the period. Bank of America Corp DE lifted its stake in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the period. Finally, Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics during the 2nd quarter valued at approximately $48,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

HOWL has been the topic of several research reports. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.